20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Schizophrenia

In brief

The purpose of this study is to evaluate the effect of AMG 747 on negative symptoms of schizophrenia in patients who are stable on current antipsychotic treatment. After a run-in period on their current antipsychotic treatment, patients will be randomized to one of the four treatment arms as add-on therapy for a treatment duration of up to 3 months.

Key facts

Study ID

NCT01568216

Run by

Amgen

People needed

121

Starts

2012-05-01

Expected to finish

2013-06-01

Last updated by the study team

2015-07-30

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) schizophrenia
• Total score on the PANSS Marder Negative Symptom Factor Scale (NSFS) ≥20
• Total score on the PANSS Marder Positive Symptom Factor Scale (PSFS) ≤ 30
• Receiving stable antipsychotic therapy for at least 8 weeks prior to screening
• Receiving a stable dose of other psychotropic agents for at least 8 weeks prior to screening
• Subject has had a stable residence or living arrangement for at least 8 weeks prior to screening and the residence or living arrangement is not anticipated to change for the duration of the study
• The subject or subject's legally acceptable representative has provided informed consent.

You may not qualify if…

• Current schizoaffective or bipolar disorder, panic disorder, obsessive compulsive disorder, evidence of mental retardation by history or clinical examination or known premorbid IQ ≤ 70
• Clinically significant suicidal ideation or suicide attempts, assaultive behavior or marked changes in mood within the 8 weeks prior to screening, or currently endorsing suicidal ideation in clinical exam
• Substance abuse (with the exception of nicotine or caffeine abuse) within the 8 weeks prior to screening, or during screening
• Substance dependence (with the exception of nicotine or caffeine dependence) within the 6 months prior to screening, or during screening
• Planning to initiate a smoking cessation therapy or otherwise substantially modify nicotine use during the study
• Positive urine drug test for substances of abuse (with the exception of positive screens for prescribed agents such as benzodiazepines).
• Other criteria may apply

Where it is running

• Research Site — Anaheim, California, United States
• Research Site — Cerritos, California, United States
• Research Site — Culver City, California, United States
• Research Site — Garden Grove, California, United States
• Research Site — Los Angeles, California, United States
• Research Site — Norwalk, California, United States
• Research Site — San Bernardino, California, United States
• Research Site — Torrance, California, United States
• Research Site — Washington D.C., District of Columbia, United States
• Research Site — North Miami, Florida, United States
• Research Site — Atlanta, Georgia, United States
• Research Site — Chicago, Illinois, United States
• Research Site — Marlton, New Jersey, United States
• Research Site — Glen Oaks, New York, United States
• Research Site — Rochester, New York, United States
• Research Site — Raleigh, North Carolina, United States
• Research Site — Dayton, Ohio, United States
• Research Site — Houston, Texas, United States
• Research Site — Glenside, South Australia, Australia
• Research Site — Melbourne, Victoria, Australia
• Research Site — Mount Claremont, Western Australia, Australia
• Research Site — Calgary, Alberta, Canada
• Research Site — Penticton, British Columbia, Canada
• Research Site — Kingston, Ontario, Canada
• Research Site — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.